Shruti Bhat PhD, MBA, Operations Excellence Expert
  • Home
  • About Shruti
  • Books
  • Insights
  • Operational Excellence
  • Research
    • Innovation Management
    • Leading Research and Development
    • Developer's Diary
  • Case Studies
  • Tools
    • Whitepapers
    • Articles >
      • Business Transformation
      • Process Improvement
      • Business Continuity
      • Change Management
      • Digital Transformation
      • Quality Improvement
    • Checklists and Templates
    • Free eBook
    • Videos
  • Blog
  • Engage Shruti
    • Consulting >
      • Operational Excellence Consulting
      • Business Transformation Consulting
      • Innovation Management Consulting
    • Workshops
  • Contact

High-Dose Aspirin May Provide Acute Migraine Relief

4/16/2010

1 Comment

 
Here are some highlights from current pharma and clinical research news, views and data-

Scientists Move Closer To Creating Equivalent Of Male Viagra For Women.  

The Los Angeles Times blog reported that "when Viagra [sildenafil] was first marketed, some sexual health experts suggested that it might work in women as well as men, providing a pharmacological aid for women with low levels of arousal (sometimes termed 'female sexual dysfunction' or 'female sexual arousal disorder')." Women haven't had great success with the little blue pill, however, which suggests "there's something about arousal in male versus female parts that differs physiologically." Now, however, researchers at Pfizer say they've made headway in finding a drug that could help some women with FSAD.  

According to the article, the breakthrough came courtesy of rabbits. Researchers administered a drug known as UK-414,495 to female rabbits and it appeared to "mimic the human body's natural processes in bolstering" excitement". By specifically blocking the enzyme in the body that checks blood flow to" female genitalia, "the drug could allow for greater blood flow and greater physiological arousal, said Chris Wayman, the lead researcher on the project" that is detailed in the British Journal of Pharmacology. The "drug would not create arousal out of nowhere," but it will "boost blood flow when accompanied by desire and sexual stimulation."  

What's more, it "will not affect desire, mood, or emotional problems," the UK's Daily Mail (4/14, Ellicott) reported. In short, "this is the first pill that claims to be an equivalent of the male Viagra."

Pfizer, however, "will not develop the drug and has said the chemical may not work in the same way in humans,while the particular chemical compound studied in this research did not prove appropriate for further development, the implications of the research could lead to the development of a product in future."  

Blood Cancer Drug Campath May Help Patients With Multiple Sclerosis.  

According to research presented at an American Academy of Neurology meeting.reports that "Genzyme Corp.'s blood cancer drug Campath [alemtuzumab] helped patients with multiple sclerosis," The drug "halted the development of disease-related disabilities and prevented relapses in 71 percent of patients in a four-year study, compared with 35 percent with Merck KGaA's competing product Rebif [interferon beta 1a]."  

InterMune Adds Ritonavir To Second Part Of Hepatitis C Treatment Study.  

InterMune Inc. said Wednesday researchers will add a new drug that promises an increased safety margin to a midstage study of a potential hepatitis C treatment after analyzing preliminary results." The company "said the first part of the study paired the experimental treatment, labeled ITMN-191 [danoprevir], with the drugs Pegasys [Peginterferon alfa-2a] and Copegus [ribavirin]," and the "second part of the study will include those drugs and the virus-fighting drug ritonavir." InterMune Chairman and CEO Dan Welch said the combination with ritonavir "appears to deliver strong efficacy and offer attractive advantages of dosing convenience and increased safety margin." 

Rituximab May Benefit Patients With Myasthenia Gravis.  

According to a study presented at an American Academy of Neurology meeting, "Rituximab (Rituxan), the anti-CD20 antibody that decreases B-cell activation, slashed autoantibody titers and improved symptoms in patients with myasthenia gravis (MG) refractory to standard therapies," Researchers said that "thirteen MG patients whose disease was not well controlled with moderate steroid doses were able to do better symptomatically and could reduce conventional treatments when rituximab was added to their therapy."  

High-Dose Aspirin May Provide Acute Migraine Relief. 

MedPage Today reported, "High-dose aspirin matched a triptan drug for relief of acute migraine," Oxford researchers found after reviewing 13 studies in which 4,222 people received either "aspirin with or without an antiemetic, placebo, or an active comparator, most often sumatriptan 50 mg or 100 mg." A "fourth of patients treated with 900 to 1,000 mg of aspirin, with or without an antiemetic, were pain free after two hours, and half of patients had no more than mild residual pain," according to a paper in The Cochrane Library. "Results for most outcomes were similar for patients treated with sumatriptan."  

Fidaxomicin May Be As Effective As Vancomycin In Patients With Clostridium Difficile Infection.  

Medscape reported, "Phase 3 clinical trial results...show that fidaxomicin is at least as effective as vancomycin (equivalent cure rates) in patients with Clostridium difficile infection (CDI)." The drug was also "associated with significantly lower recurrence rates, particularly in patients infected with the emerging hypervirulent BI/NAP1/027 subtype of C difficile that has proven especially difficult to treat," researchers in Canada explained. Notably, the drug's manufacturer, Optimer Pharmaceuticals, "plans to submit a New Drug Application for fidaxomicin to the US Food and Drug Administration later this year, according to the company website."  
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
1 Comment
Williams link
3/22/2025 07:52:36 pm

Interesting post. I'd be curious to learn more about where we are medically 15 years on from this study.

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement
    To contact Dr. Shruti Bhat text or WhatsApp at 1.403.969.6219

    New Book Released!

    Revolutionizing Industries with Lean Six Sigma

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    Agile
    Artificial Intelligence
    Automation
    Biotechnology
    Books
    Business Continuity
    Business Turnaround
    Case Studies
    Change Management
    Checklists
    Chemical Industry
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    Insights
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    MSMEs
    Nanotechnology
    Operational Excellence
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    R&D Leadership
    Robotics
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    Templates
    TQM
    Videos
    Voice Of Customer
    Whitepaper
    Workshops

    Shruti's books...

    Picture
    top ten strategic decision-making tools for operational excellence
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    how to lead a successful business transformation
    leading organizations through crisis
    emotional intelligence
    how to overcome challenges of creating effective teams
    modular kaizen Vs Blitz kaizen
    How to increase employee engagement as a new boss

Connect with Dr. Shruti Bhat at- ​Twitter, YouTube, LinkedIn​

© Copyright 1992- 2025 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
Subscribe to Operational Excellence Academy YouTube Channel
​Subscribe to Operational Excellence Academy YouTube Channel
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media